Myle T Hoang

US Patent:

20050009815, Jan 13, 2005

Filed:

Nov 22, 2002

Appl. No.:

10/496614

Inventors:

Robert DeVita - Westfield NJ, US
Lehua Chang - Ramsey NJ, US
MyLe Hoang - Colonia NJ, US
JinLong Jiang - Scotch Plains NJ, US
Peter Lin - Edison NJ, US
Andreas Sailer - Edison NJ, US

International Classification:

A61K031/541
A61K031/5377
A61K031/496
A61K031/4709

US Classification:

514227500, 514232500, 514253060, 514313000, 544060000, 544126000, 544363000, 546159000

Abstract:

The present invention is concerned with compounds of the general Formula I: and pharmaceutically acceptable salts thereof, which are useful as melanin concentrating hormone receptor antagonists, particularly MCH-1R antagonists. As such, compounds of the present invention are useful for the treatment or prevention of obesity or eating disorders associated with excessive food intake and complications thereof, osteoarthritis, certain cancers, AIDS wasting, cachexia, frailty (particularly in elderly), mental disorders stress, cognitive disorders, sexual function, reproductive function, kidney function, locomotor disorders, attention deficit disorder (ADD), substance abuse disorders and dyskinesias, Huntington's disease, epilepsy, memory function, and spinal muscular atrophy. Compounds of formula I may therefore be used in the treatment of these conditions, and in the manufacture of a medicament useful in treating these conditions. Pharmaceutical formulations comprising one of the compounds of formula (I) as an active ingredient are disclosed, as are processes for preparing these compounds.

US Patent:

20050026915, Feb 3, 2005

Filed:

Nov 22, 2002

Appl. No.:

10/496615

Inventors:

Robert DeVita - Westfield NJ, US
Lehua Chang - Ramsey NJ, US
Danny Chaung - Clark NJ, US
MyLe Hoang - Colonia NJ, US
JinLong Jiang - Scotch Plains NJ, US
Peter Lin - Edison NJ, US
Andreas Sailer - Edison NJ, US
Jonathan Young - Kendall Park NJ, US

International Classification:

A61K031/541
A61K031/5377
A61K031/496
A61K031/4709
C07D417/02
C07D413/02
C 07D 4 3/02

US Classification:

514227800, 514232500, 514253060, 514313000, 544060000, 544363000, 546159000, 544126000

Abstract:

The present invention is concerned with compounds of the general Formula I: and pharmaceutically acceptable salts thereof, which are useful as melanin concentrating hormone receptor antagonists, particularly MCH-1R antagonists. As such, compounds of the present invention are useful for the treatment or prevention of obesity or eating disorders associated with excessive food intake and complications thereof, osteoarthritis, certain cancers, AIDS wasting, cachexia, frailty (particularly in elderly), mental disorders stress, cognitive disorders, sexual function, reproductive function, kidney function, locomotor disorders, attention deficit disorder (ADD), substance abuse disorders and dyskinesias, Huntington's disease, epilepsy, memory function, and spinal muscular atrophy. Compounds of formula I may therefore be used in the treatment of these conditions, and in the manufacture of a medicament useful in treating these conditions. Pharmaceutical formulations comprising one of the compounds of formula (I) as an active ingredient are disclosed, as are processes for preparing these compounds.

US Patent:

20090012061, Jan 8, 2009

Filed:

Sep 9, 2005

Appl. No.:

11/662396

Inventors:

Timothy A. Blizzard - Princeton NJ, US
Carolyn A. Buser-Doepner - Harleysville PA, US
Douglas E. Frantz - Downingtown NJ, US
Kelly Hamilton - North Wales PA, US
Myle Hoang - Colonia NJ, US
Ling Lee - Lansdale PA, US
Christopher R. Moyes - Hertfordshire, GB
Jerry A. Murry - New York NY, US
Arash Soheili - Iselin NJ, US

International Classification:

G01N 33/574
C12N 9/99
A61K 31/403
A61K 31/428
C07C 271/06
A61K 31/27
A61K 31/47
C07D 215/38
C07C 39/12
A61K 31/05
C07C 275/28
A61K 31/17
A61K 31/165
A61K 31/415
A61K 31/44
A61K 31/5415
A61K 31/551
A61P 35/00

US Classification:

514218, 435 71, 435184, 514411, 514367, 560 27, 514535, 514313, 546159, 568719, 514732, 564 52, 514598, 514617, 514406, 514344, 5142262, 514418

Abstract:

The present invention relates to a method of treating cellular proliferative diseases, in particular cancer, which comprises administering a modulator of the activity of the mitotic kinesin KSP, wherein the activity of the KSP modulator is dependent on the presence of microtubules. It is believed that the KSP modulators utilized in the instant method bind to the KSP protein in a previously unreported manner, since the compounds do not bind competitively with respect to either microtubules or ATP, the substrates of KSP. The modulators useful in the instant methods are furthermore not active against the non-microtubule stimulated activity of KSP. Cellular proliferative diseases that may be treated using the method disclosed herein are, for example cancer, hyperplasias, restenosis, cardiac hypertrophy, immune disorders and inflammation.